University of Minnesota. Driven to Discover.
Admission to an Ebola treatment unit was tied to a 38% drop in secondary cases.
Four of the 7 new cases were reported in Katwa, the latest outbreak hot spot.
The drug, zoliflodacin, was highly effective in treating urogenital and rectal infections but not pharyngeal cases.
Immune response lasted 2.5 years for the vaccines, the longest yet in ongoing studies of Ebola immunization.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.